Abstract:ObjectiveRecent advances in next-generation sequencing (NGS) have provided new methods for preimplantation genetic screening (PGS) of human embryos from IVF cycles. The present study aimed to investigate the effects of NGS screening on clinical pregnancy and ongoing pregnancy outcomes of single embryo transfer for PGS patients in comparison to array comparative genomic hybridization (aCGH) screening.DesignA total of 131 PGS patients at mean age 35.6 ± 3.4 years (ranging 28 to 39 years old) who met the inclusion criteria were randomized into two groups: 1) NGS (Group A): patients (n=66) had embryos screened with NGS and 2) aCGH (Group B): patients (n=65) had embryos screened with aCGH. The cohort patients requested PGS due to recurrent pregnancy loss (n=59), repeated implantation failure (n=48) and previous aneuploid conceptions (n=24).Materials and MethodsFor both NGS and aCGH groups, embryos were cultured to blastocyst stage and trophectoderm biopsy was performed on Day 5 (up to 11:00 pm). Blastocysts were vitrified individually after biopsy. One euploid blastocyst was transferred to individual patients based on the results of PGS with either NGS (Group A) or aCGH (Group B). Clinical pregnancy and ongoing pregnancy rates per transfer were compared between the two groups. Clinical pregnancy was defined as an intrauterine gestational sac with fetal heartbeat visualized by ultrasound examination at week 8 after embryo transfer. Ongoing pregnancy was defined as continuing pregnancy at ≥ 20 weeks of gestation. The categorical variables were analyzed by Chi-square analysis or Fisher’s exact test as appropriate. A two-tailed value of p <0.05 was considered statistically significant.ResultsThere were no significant differences in female patient’s mean age, Day 3 FSH, AMH, E2, antral follicle number between the two groups (p >0.05). NGS screening identified single euploid blastocysts for transfer and resulted in similar clinical pregnancy rates for PGS patients compared to aCGH screening (69.8% vs. 65.6%, respectively, p >0.05). There was no significant difference in ongoing pregnancy rates between the NGS and aCGH groups (68.3% vs. 63.9%, respectively, p >0.05). The miscarriage rates were also comparable between Group A and Group B (1.5% vs. 1.6%, respectively, p >0.05).ConclusionsWhile NGS screening has been recently introduced to assist IVF patients, this is the first randomized clinical study on the efficiency of NGS for single embryo transfer in comparison to aCGH. With the observed high accuracy of 24-chromosome screening and the resulting high clinical pregnancy and ongoing pregnancy rates, NGS has demonstrated an efficient, robust high-throughput technology for selection of single embryo for transfer. ObjectiveRecent advances in next-generation sequencing (NGS) have provided new methods for preimplantation genetic screening (PGS) of human embryos from IVF cycles. The present study aimed to investigate the effects of NGS screening on clinical pregnancy and ongoing pregnancy outcomes of single embryo transfer for PGS patients in comparison to array comparative genomic hybridization (aCGH) screening. Recent advances in next-generation sequencing (NGS) have provided new methods for preimplantation genetic screening (PGS) of human embryos from IVF cycles. The present study aimed to investigate the effects of NGS screening on clinical pregnancy and ongoing pregnancy outcomes of single embryo transfer for PGS patients in comparison to array comparative genomic hybridization (aCGH) screening. DesignA total of 131 PGS patients at mean age 35.6 ± 3.4 years (ranging 28 to 39 years old) who met the inclusion criteria were randomized into two groups: 1) NGS (Group A): patients (n=66) had embryos screened with NGS and 2) aCGH (Group B): patients (n=65) had embryos screened with aCGH. The cohort patients requested PGS due to recurrent pregnancy loss (n=59), repeated implantation failure (n=48) and previous aneuploid conceptions (n=24). A total of 131 PGS patients at mean age 35.6 ± 3.4 years (ranging 28 to 39 years old) who met the inclusion criteria were randomized into two groups: 1) NGS (Group A): patients (n=66) had embryos screened with NGS and 2) aCGH (Group B): patients (n=65) had embryos screened with aCGH. The cohort patients requested PGS due to recurrent pregnancy loss (n=59), repeated implantation failure (n=48) and previous aneuploid conceptions (n=24). Materials and MethodsFor both NGS and aCGH groups, embryos were cultured to blastocyst stage and trophectoderm biopsy was performed on Day 5 (up to 11:00 pm). Blastocysts were vitrified individually after biopsy. One euploid blastocyst was transferred to individual patients based on the results of PGS with either NGS (Group A) or aCGH (Group B). Clinical pregnancy and ongoing pregnancy rates per transfer were compared between the two groups. Clinical pregnancy was defined as an intrauterine gestational sac with fetal heartbeat visualized by ultrasound examination at week 8 after embryo transfer. Ongoing pregnancy was defined as continuing pregnancy at ≥ 20 weeks of gestation. The categorical variables were analyzed by Chi-square analysis or Fisher’s exact test as appropriate. A two-tailed value of p <0.05 was considered statistically significant. For both NGS and aCGH groups, embryos were cultured to blastocyst stage and trophectoderm biopsy was performed on Day 5 (up to 11:00 pm). Blastocysts were vitrified individually after biopsy. One euploid blastocyst was transferred to individual patients based on the results of PGS with either NGS (Group A) or aCGH (Group B). Clinical pregnancy and ongoing pregnancy rates per transfer were compared between the two groups. Clinical pregnancy was defined as an intrauterine gestational sac with fetal heartbeat visualized by ultrasound examination at week 8 after embryo transfer. Ongoing pregnancy was defined as continuing pregnancy at ≥ 20 weeks of gestation. The categorical variables were analyzed by Chi-square analysis or Fisher’s exact test as appropriate. A two-tailed value of p <0.05 was considered statistically significant. ResultsThere were no significant differences in female patient’s mean age, Day 3 FSH, AMH, E2, antral follicle number between the two groups (p >0.05). NGS screening identified single euploid blastocysts for transfer and resulted in similar clinical pregnancy rates for PGS patients compared to aCGH screening (69.8% vs. 65.6%, respectively, p >0.05). There was no significant difference in ongoing pregnancy rates between the NGS and aCGH groups (68.3% vs. 63.9%, respectively, p >0.05). The miscarriage rates were also comparable between Group A and Group B (1.5% vs. 1.6%, respectively, p >0.05). There were no significant differences in female patient’s mean age, Day 3 FSH, AMH, E2, antral follicle number between the two groups (p >0.05). NGS screening identified single euploid blastocysts for transfer and resulted in similar clinical pregnancy rates for PGS patients compared to aCGH screening (69.8% vs. 65.6%, respectively, p >0.05). There was no significant difference in ongoing pregnancy rates between the NGS and aCGH groups (68.3% vs. 63.9%, respectively, p >0.05). The miscarriage rates were also comparable between Group A and Group B (1.5% vs. 1.6%, respectively, p >0.05). ConclusionsWhile NGS screening has been recently introduced to assist IVF patients, this is the first randomized clinical study on the efficiency of NGS for single embryo transfer in comparison to aCGH. With the observed high accuracy of 24-chromosome screening and the resulting high clinical pregnancy and ongoing pregnancy rates, NGS has demonstrated an efficient, robust high-throughput technology for selection of single embryo for transfer. While NGS screening has been recently introduced to assist IVF patients, this is the first randomized clinical study on the efficiency of NGS for single embryo transfer in comparison to aCGH. With the observed high accuracy of 24-chromosome screening and the resulting high clinical pregnancy and ongoing pregnancy rates, NGS has demonstrated an efficient, robust high-throughput technology for selection of single embryo for transfer.

Selecting single euploid blastocysts for transfer with NGS significantly improves IVF treatment outcomes: a randomized study

Application of Preimplantation Genetic Testing for Aneuploidies with Next-Generation Sequencing in Women with Advanced Maternal Age

Comprehensive Preimplantation Genetic Testing by Massively Parallel Sequencing

Randomized comparison of next-generation sequencing and array comparative genomic hybridization for preimplantation genetic screening: a pilot study

Selection of Single Blastocysts for Transfer Via Time-Lapse Monitoring Alone and with Next-Generation Sequencing to Reduce Multiple Pregnancies: A Randomized Pilot Study.

Selection of Single Euploid Blastocysts for Transfer Via Preimplantation Genetic Screening with Either Next-Generation Sequencing or Array Comparative Genomic Hybridization: a Randomized Pilot Study

Euploid blastocysts implant irrespective of their morphology after NGS-(PGT-A) testing in advanced maternal age patients

Clinical outcome of preimplantation genetic diagnosis and screening using next generation sequencing

A pilot proof-of-principle study to compare fresh and vitrified cycle preimplantation genetic screening by chromosome microarray and next generation sequencing

Selection of Competent Blastocysts for Transfer by Combining Time-Lapse Monitoring and Array CGH Testing for Patients Undergoing Preimplantation Genetic Screening: a Prospective Study with Sibling Oocytes

Non-invasive Embryo Selection Strategy for Clinical IVF to Avoid Wastage of Potentially Competent Embryos

Microarray Pre-Implantation Genetic Screening Significantly Improves Clinical Outcomes with Vitrified-Thawed Embryo Transfer

A Rapid NGS-Based Preimplantation Genetic Testing for Chromosomal Abnormalities in Day-3 Blastomere Biopsy Allows Embryo Transfer Within the Same Treatment Cycle.

Selection of Euploid Blastocysts for Cryopreservation with Array Comparative Genomic Hybridization (acgh) Results in Increased Implantation Rates in Subsequent Frozen and Thawed Embryo Transfer Cycles

Preimplantation Genetic Testing for Aneuploidy Could Not Improve Cumulative Live Birth Rate among 705 Couples with Unexplained Recurrent Implantation Failure

In Vitro Fertilization with Single-nucleotide Polymorphism Microarray-based Preimplantation Genetic Testing for Aneuploidy Significantly Improves Clinical Outcomes in Infertile Women with Recurrent Pregnancy Loss: A Randomized Controlled Trial

Evaluating the Application Value of NGS-based PGT-A by Screening Cryopreserved MDA Products of Embryos from PGT-M Cycles with Known Transfer Outcomes

Multi-omics PGT: re-evaluation of euploid blastocysts for implantation potential based on RNA sequencing

Live Birth with or without Preimplantation Genetic Testing for Aneuploidy

Evaluation of Preimplantation Genetic Testing Based on Next-Generation Sequencing for Balanced Reciprocal Translocation Carriers.

Impact of Multiple Vitrification-Warming Procedures and Insemination Methods on Pregnancy and Neonatal Outcomes in Preimplantation Genetic Testing for Aneuploidy